The key events responsible for mouse liver tumors induced by a pesticide (viz., pronamide) were investigated in a series of studies employing molecular, biochemical, cellular, and apical endpoints. Based on these studies, it was demonstrated that the liver tumors were mediated by a mode of action (MoA) involving nuclear receptors (NRs) through the following key events: (1) CAR and PPAR-␣ receptor activation, (2) increased hepatocellular proliferation, eventually leading to (3) hepatocellular tumors. Specifically, gene expression analysis indicated robust, simultaneous coactivation of the CAR and PPAR-␣ NRs, as indicated by the induction of hepatic Cyp2b10 and Cyp4a10 transcripts, in response to dietary administration of pronamide to mice. The presence of hepatocellular hypertrophy and peroxisome proliferation was indicative of the activation of these two NRs at carcinogenic dose levels. Demonstrated induction of Cyp2b10 gene and protein, however, was not accompanied by enhancement of the corresponding enzyme activity (7-pentoxyresorufin-O-dealkylase (PROD)), suggesting that pronamide administration resulted in mechanism-based (suicide) inhibition of the enzyme in vivo. This was confirmed with an in vitro assay for suicide inhibition, where pronamide and/or its metabolites irreversibly inhibited Cyp2b10-mediated PROD activity. Analysis of hepatocellular proliferation via BrdU incorporation indicated a clear dose-and duration-related induction of S-phase DNA synthesis only in animals treated at and above the carcinogenic dose level. The available MoA data were evaluated for weight-of-evidence based upon the Bradford Hill criteria, followed by a human relevance framework. The conclusion from this evaluation is that pronamide-induced mouse liver tumors occur via an NR-mediated MoA involving CAR and PPAR-␣ activation and this MoA is not relevant to humans based on qualitative/quantitative differences between mice and humans.
FIG. 1. Chemical structure of pronamide.
MoAs and potential relevance to humans is the nuclear receptor (NR)-mediated effects such as activators of the constitutive androstane receptor (CAR), pregnane X receptor (PXR), and peroxisome proliferator-activated receptor-alpha (PPAR-␣) (reviewed in Corton et al., 2014; Elcombe et al., 2014) .
The herbicide pronamide (propyzamide or 3,5-dichloro-N-(1,1-dimethyl-2-propynyl)benzamide; CAS no. 23950-58-5; Fig. 1 ) is a selective, pre-and post-emergence herbicide used to control annual and perennial grasses and some broadleaf weeds. The herbicidal MoA affects root development and growth in plants, specifically by inhibiting cell division, potentially through binding a microtubule-associated protein and interfering with spindle fiber formation and mitosis. Pronamide has low acute oral toxicity and was consistently negative in a battery of genotoxicity tests (summarized in Supplementary data; Supplementary Appendix table 1). Several short-term and three separate chronic/carcinogenicity studies have been conducted using pronamide in multiple strains of mice across a wide-range of dose levels (unpublished study reports: Larson, 1974; Newberne, 1982; Stebbins and Brooks, 2004) . In general, mice in each study had a similar response to repeat-dose pronamide administration, although only the most recent study is analyzed in the context of the MoA analysis, as this conformed to the most current test guidelines. The general trend of high-dose mouse liver tumors supports the conclusion that pronamide induces treatment-related mouse liver tumors. Treatment-related hepatic tumors were not identified in a 2-year carcinogenicity study performed in CD rats (unpublished study report: Bailey, 1990) .
In the 2004 carcinogenicity study, male and female Crl:CD1(ICR) mice were administered 0, 5, 50, or 250-mg pronamide/kg bw/day (mkd) via the diet for 18 months (unpublished study report: Stebbins and Brooks, 2004) . Treatmentrelated, statistically identified increases in liver weight were identified in male and female mice given 50 and 250 mkd. Specifically, when compared with controls, the mean relative liver weight of males treated with 250 mkd was increased 2.9-fold and females increased 2.1-fold. Histopathologic, treatment-related effects in male and female mice treated with 250-mkd pronamide included hepatocellular hypertrophy, bile stasis, and bile duct hyperplasia, whereas the only effects noted in the lower dose groups were slight centrilobular hypertrophy and very slight bile duct hyperplasia in males dosed with 50-mkd pronamide. Increases in treatment-related hepatocellular adenomas and/or carcinomas were identified in males and females at 250 mkd (Table 1) . As there were no clear differences between sexes, only males were used for the MoA investigation for scientific and animal welfare considerations.
The key events responsible for pronamide-induced mouse liver tumors were investigated in a series of studies utilizing apical, molecular, biochemical, and cellular end points and are described herein. These data were then employed to evaluate potential MoAs for pronamide-induced mouse liver tumors and their potential relevance to humans.
MATERIALS AND METHODS

Animals and treatment.
The MoA and previous repeat-dose toxicity studies were primarily conducted on approximately 8-weekold male Crl:CD1(ICR) mice from Charles River Laboratories, Inc. (Portage, MI). The studies were performed at The Dow Chemical Company, Toxicology & Environmental Research & Consulting, Midland, MI, which is accredited by the American Association for Accreditation of Laboratory Animal Care. All animal care and use activities were reviewed and approved by the Institutional Animal Care and Use Committee. The MoA study included 7-, 14-, and 28-day treatment periods (n = 10/group), along with a recovery group that was treated for 28 days followed by a 35-day recovery period (n = 10/group).
Dietary test article preparation and analysis.
Pronamide was administered in the diet, (LabDiet Certified Rodent Diet no. 5002, PMI Nutrition International, St. Louis, MO), with analytical confirmation of dietary concentrations. Feed consumption was determined for all mice by weighing feed containers at the beginning and end of the respective exposure period. Test material intake was calculated upon completion of the study using test material concentrations in the feed, body weights, and measured feed consumption.
Osmotic pumps. For the 7-day treatment group, 1 day prior to exposure mice were implanted with mini-osmotic pumps (Model, 2001 ; Alzet Corporation, Palo Alto, CA) containing bromodeoxyuridine (BrdU; a structural analog of thymidine that incorporates into nuclear DNA and is used as a surrogate marker of cell proliferation). For the 14-day, 28-day, and 35-day recovery groups, mice were implanted with the pumps at the appropriate time to allow for continuous administration of BrdU for the final 7 days of the treatment/recovery. The implanted osmotic pumps were filled with a solution of 20-mg/ml BrdU in phosphate buffered saline (pH 7.6), delivered at a rate of 1 l/h. Clinical data and pathology. Mice submitted for necropsy were weighed (with the implanted osmotic pump in situ), anesthetized by inhalation of isoflurane/O 2 , and blood samples were obtained from the orbital sinus. The animals were then euthanized by decapitation. The osmotic pumps were removed and weighed. The weights of the osmotic pumps were subtracted from the recorded body weights to determine the final body weight. The skin was reflected from the carcass, the abdominal cavity opened, and the liver excised and weighed. In addition, a 2-3-cm segment of the proximal duodenum was excised, flushed with fixative, and placed in the same fixative with the liver tissue, which served as a positive control for osmotic pump functionality and immunohistochemistry. The upper quarter of the left lateral liver lobe was processed in RNAlater for targeted gene expression analysis. The upper middle quarter of the left lateral lobe was trimmed and preserved in neutral phosphatebuffered 10% formalin and was used for histological examination and BrdU proliferation analysis. The lower quarter of the left lateral liver lobe and the lower portion of the medial liver lobe were flash frozen and stored at −80
• C for further analyses, including enzyme activity analysis. The livers of all mice were processed by standard histologic procedures. Paraffin-embedded tissues were sectioned approx- imately 6 m thick, stained with hematoxylin and eosin (H&E), and examined by a veterinary pathologist using a light microscope.
Hepatic gene expression. Liver samples preserved in RNAlater from all exposure groups were used for RNA isolation (n = 10 animals/group). Total RNA was extracted using the Qiagen RNeasy kit following the manufacturer's protocol (Qiagen Inc., Valencia, CA). RNA quantity and quality were assessed by a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), respectively. Only samples with an OD 260/280 ratio greater than 1.8, clearly defined 28S and 18S bands, and acceptable RNA Integrity Numbers (generally Ͼ7) from the BioAnalyzer were used for gene expression studies.
Total RNA was treated with DNase enzyme to avoid DNA contamination. Gene expression studies were conducted with an Applied Biosystems 7500 fast real-time Polymerase Chain Reaction system (Applied Biosystems, Foster City, CA) using Applied Biosystems (ABI) TaqMan Gene Expression Assays. Due to the nature of the TaqMan system, dissociation curves were not required to verify the specificity of the PCR reactions. Expression of the following mouse genes was investigated: (1) Cyp1a1 "AhR-associated gene", ABI assay ID: Mm00487218 m1; (2) Cyp2b10 "CAR-associated gene", ABI assay ID: Mm00456591 m1; (3) Cyp3a11 "PXR-associated gene", ABI assay ID: Mm00731567 m1; (4) Cyp4a10 "PPAR␣-associated gene", ABI assay ID: Mm02601690 gH; (5) Acox1 "PPAR-␣ response gene" Mouse-Mm00443579 m1; (6) Pmp70 "PPAR-␣ response gene" Mouse-Mm00436150 m1; (7) Cte1 "PPAR-␣ response gene" Mouse-Mm00506625 m1. β-actin was used as the internal standard (ABI TaqMan ID: mouse, Mm00607939 s1).
Data were analyzed by generation of the threshold cycle (Ct) and delta Ct (⌬ Ct) values for all genes. Each sample was analyzed in triplicate for the reference and target genes. Amplification curves were processed using Sequence Detection Software 1.4 (ABI). Gene expression was quantified using the comparative Ct method (⌬ ⌬ Ct) (Schmittgen and Livak, 2008) . For this method, the amount of target mRNA for each treatment group was expressed relative to an endogenous reference or housekeeping gene (␤-actin) and relative to vehicle control animals. The mean Ct of the housekeeping gene was subtracted from the mean Ct of the target genes (⌬ Ct). The mean ⌬ Ct value from each treatment group was then subtracted from the mean ⌬ Ct for the vehicle control group to generate the ⌬ ⌬ Ct value that was used to calculate the fold-induction for that treatment group, relative to controls.
Microsome isolation.
Frozen liver samples were thawed on ice and homogenized using a Potter-Elvehjem apparatus. Microsomes were isolated using the method outlined by Guengerich (1982) .
Total microsomal protein levels were determined for individual animals using the Pierce BCA method (Pierce Chemical Co., Rockford, IL).
Western blot analysis. Immunoreactive Cyp2b10 protein levels were assessed by Western immunoblotting using microsomes prepared from the mouse liver. Briefly, for each sample 30 g of protein was applied for sodium dodecyl sulfate-polyacrylamide gel electrophoresis and proteins were transferred electrophoretically to nitrocellulose membranes for immunoblotting. Membranes were pre-blocked for 1 h using casein buffer followed by polyclonal rabbit anti-Cyp2b10 antibodies (Millipore, Billerica, MA) for at least 2 h at room temperature with shaking. Membranes were rinsed with Tris-buffered saline with 0.1% Tween-20 buffer and probed with horseradish peroxidase-conjugated secondary antibodies (goat, anti-rabbit IgG, Millipore) for at least 45 min at room temperature with shaking. Immunoreactive bands were visualized on a Fluor-S multi-imager (BioRad, Hercules, CA) with SuperSignal detection systems (ThermoScientific, Waltham, MA). Commercially available control and phenobarbital (PB)-treated liver microsomes were included in each blot.
In vitro enzyme activity assays. Enzyme activity (PROD) was determined for Cyp2b10 using pentoxyresorufin as the substrate. Activities were measured using a microplate fluorometric method (Kennedy and Jones, 1994) . Briefly, this method involves the measurement of the in vitro O-dealkylation of 7-pentoxyresorufin to a highly fluorescent product, resorufin, by microsomal-mixed function oxidases (Burke and Mayer, 1983) . Samples analyzed included microsomes prepared from pronamide-treated mouse liver samples from the 7-day treatment group, as well as dimethyl sulfoxide (DMSO) control and commercially available PB-induced liver microsomes.
In vitro assay for mechanism-based (suicide) inhibition of p450 enzyme activity. Commercially available PB-induced rat liver microsomes (Celsis/In Vitro Technologies, Catalog no. M70001, Lot no. TVZ; 25 g/well), along with reaction buffer and PROD fluorometric substrate, were prepared and pipetted into a 96-well plate for assay conduct. To this mixture an appropriate concentration of one of the following test substances was added: solvent (0.1% DMSO), negative control for inhibition (PB; 1-500M), positive control for inhibition (curcumin; 10-80M), or pronamide (1-500M). The enzymatic activity was determined by the rate of PROD conversion to resorufin (pmol/min/mg protein) as detected by a fluorometric plate reader (fmax, Molecular Devices, Sunnyvale, CA) in a 20-min kinetic assay (Burke and Mayer, 1983; Kennedy and Jones, 1994) . (BrdU) . In the MoA study where CD-1 mice were implanted with BrdU-containing osmotic pumps, levels of hepatocyte S-phase DNA synthesis were determined using 5-bromo-2'-deoxyuridine (BrdU) immunohistochemistry for the identification of BrdU incorporation into nuclear DNA (Eldridge et al., 1990) . At necropsy, sections of the liver were treated as described previously, processed by standard techniques, and mounted on glass slides. Tissue was stained for BrdU using the manufacturer's protocol (BD Biosciences, San Diego, CA) with modified heat-induced antigen retrieval followed by addition of primary and secondary antibodies to selectively detect DNA containing BrdU. DAB (3,3'-diaminobenzidine) chromagen (brown stain) was used to identify BrdU containing nuclei and the slides were counterstained with hematoxylin (purple stain) to visualize tissue morphology and negatively staining nuclei. A small section of duodenum from each mouse was also processed and stained to serve as a control for confirming systemic availability of BrdU and for immunohistochemical staining. Proliferation in CD-1 mice was evaluated using light microscopy where positively stained nuclei were scored as percentages based on counting 1000 total hepatocytes in each of the three hepatolobular zones: centrilobular, midzonal, and periportal regions. All BrdU slides were coded and read blind.
Statistics. Means and standard deviations were calculated for all continuous data. All parameters examined statistically (feed consumption and targeted gene expression are addressed separately) were first tested for equality of variance using Bartlett's test (Winer, 1971) . If the results from Bartlett's test were significant at ␣ = 0.01, then the data for the parameter were subjected to a transformation to obtain equality of the variances. The transformations that were examined were the common log, the inverse, the square root, the arc sine square root, and rank. The data were then reviewed and an appropriate form of the data was selected. The selected form of the data was then subjected to the appropriate parametric analysis as described below.
In-life body weights, terminal body weight, liver weight, relative liver weight, cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), enzyme activity, and BrdU for proliferation were evaluated using a one-way ANOVA (Steel and Torrie, 1960) with the factor of dose. Comparisons of individual dose groups with the control group were made with Dunnett's test (␣ = 0.05) only when a statistically significant dose effect existed (Table 3 , otherwise data not shown). Targeted gene expression was quantified using the comparative Ct method (⌬ ⌬ Ct); however, statistical analysis was not performed.
Determination of treatment-related effects was based on sound scientific principles such as biological plausibility, comparison with concurrent and historical control data, and doseresponse relationships. For example, for a relative liver weight increase to be considered treatment related, concomitant histopathological observations such as hepatocellular hypertrophy were required. In general, a treatment-related interpretation was based on the entirety of the data from a given study, or across multiple studies, for consistency and robustness of a biological response.
RESULTS
The proposed MoA for the pronamide-induced mouse liver tumors is similar to the MoA for a prototypical NR activator (i.e., PB and peroxisome proliferators). The key events for the pronamide-induced mouse liver tumors, shown in Table 2 , include: activation of the NRs, induction of hepatocellular proliferation, and tumor formation. The data that support these key events are described in subsequent sections herein.
Test Material Intake
For the MoA study, the targeted dietary dose levels of 0, 5, 20, 250, and 500-mg/kg/day pronamide administered for 7 days were 0, 5.4, 22.4, 264, and 523 mkd, respectively; for 14 days dose levels corresponded to time-weighted average doses of 0, 5.4, 20.8, 255 , and 509-mkd, respectively; for 28 days dose levels corresponded to time-weighted average doses of 0, 5.2, 20.9, 261, and 522 mkd, respectively; for 28 days with a 35-day recovery period, dose levels corresponded to time-weighted average doses of 0, 5.2, 20.7, 267, and 535 mkd, respectively. Dose confirmation of all pronamide test diets ranged from 95.7 to 106.9% of the targeted concentrations with a relative standard deviation between 3.1 and 6.9%.
NR (CAR/PXR and PPAR-␣) activation.
The activation of NRs by pronamide has not been investigated directly; however, a diagnostic, surrogate response of NR activation is commonly associated with a specific pattern of induction of hepatic xenobiotic metabolizing enzymes as biomarkers, i.e., cytochrome p450s (Cohen, 2010; Elcombe et al., 2014; Lake, 2009; Ueda et al., 2002) . Gene expression analysis was utilized to investigate (i.e., rulein or rule-out) NR-mediated pathways related to rodent hepatocarcinogenesis in hepatic tissue from pronamide-treated mice from the MoA study including: Aryl hydrocarbon Receptor (AhR), CAR, PXR, and PPAR-␣ signaling. Specifically, gene expression responses for Cyp1a1, Cyp2b10, Cyp3a11, and Cyp4a10 were examined as biomarkers for the activation of AhR (Nebert et al., 2000; Ueda et al., 2006; Whitlock, 1999) , CAR (Honkakoski et al., 1998; Kawamoto et al., 1999; Wei et al., 2000) , PXR (Kliewer et al., 1998; Xie et al., 2000) , and PPAR-␣ (Aldridge et al., 1995; Palmer et al., 1994) signaling pathways, respectively. In addition, other transcript biomarkers for peroxisome proliferation were evaluated, including Acox1, Cte1, and Pmp70.
After 7 days of pronamide treatment, there was a clear biological signature of the activation of CAR/PXR and PPAR-␣ NRs, when measured at the gene expression level. Specifically for CAR activation, Cyp2b10 showed a clear, dose-related increase in transcript level when compared with control animals of 2.7-, 10.1-, 330.4-, and 408.2-fold at 5, 20, 250, and 500-mkd pronamide, respectively (Table 3 ). This magnitude of induction at 250 and 500 mkd for Cyp2b10 was similar to a contemporary, but unrelated, internal study with PB at a carcinogenic concentration (150-mkd PB in the diet for 7 days), where PB induced a 474.4-fold induction . The fold-change induction of Cyp2b10 at 5 and 20 mkd indicated slight activation of the CAR NR, but these fold changes for this gene were not considered a biologically significant induction when compared with a car- cinogenic dose of a prototypical activator such as PB. Interestingly, at the 7-day time point the PXR-inducible Cyp3a11 transcript was induced to a similar degree at carcinogenic dose levels when compared with the response of PB. Specifically, pronamide induced a 4.2-and 6.0-fold induction at 250 and 500 mkd, respectively (Table 3) , whereas in a separate, contemporary study, 150-mkd PB induced a 2.3-fold increase . Several compounds, including PB, are known to co-activate the CAR and PXR pathways, and these pathways have overlapping genes and potentially overlapping functions (Elcombe et al., 2014; Scheer et al., 2008) . Although both CAR and PXR are activated for pronamide, the available data indicate that CAR is the predominant response and PXR may be less influential with respect to NR activation in the liver. The PPAR-␣-inducible transcripts indicated a peroxisomal proliferative phenotype, when measured after 7 days of pronamide dietary administration. Specifically, Cyp4a10 was unchanged at the 5-mkd dose level and induced to a minor degree (17.1-fold) at 20 mkd (Table 3) . Administration of 250-or 500-mkd pronamide induced a robust, biologically significant increase in Cyp4a10 transcript of 286.3-or 332.4-fold, respectively. This fold-induction was similar to that identified in a separate, but contemporary, internal study with animals administered the prototypical agonist clofibric acid (CFA) for 10 days where an increase of 523.9-fold was seen (Stagg et al., 2012) . The panel of other peroxisomal-related genes was similarly induced as with CFA, supporting the interpretation that pronamide acts as an activator of PPAR-␣, i.e., is a peroxisome proliferator. These included Acox1, Cte1, and Pmp70, which were markedly induced with pronamide at 250 (4.8-, 40.1-, and 3.3-fold, respectively) and 500 mkd (3.9-, 52.9-, and 2.7-fold, respectively) but not to a biologically significant degree at 5 (1.1-, 1.4-, and 1.1-fold, respectively) or 20 mkd (1.2-, 2.4-, and 1.1-fold, respectively) ( Table 3) .
The AhR-responsive Cyp1a1 transcript was essentially unchanged at all dose levels, indicating that pronamide is not a direct activator for the AhR. The minor transcript increases are not consistent with a direct activator of the receptor, and instead are attributed to a general, non-specific p450 induction (Table 3 ) (Boverhof et al., 2006; Corcos et al., 1998; Geter et al., 2014) .
The results of the targeted gene expression analysis revealed similar changes after 14 days of pronamide administration when compared with those seen with 7 days of treatment. For Cyp2b10 there was a 1.1-, 3.3-, 117.0-, and 131.2-fold induction for 5, 20, 250, and 500-mkd pronamide, respectively, when compared with control (Table 3) . Cyp3a11 was also consistent with the 7-day time point in that there was no biologically significant alteration in the transcript levels at the 5-or 20-mkd dose levels, but an increase of 3.7-and 3.3-fold at 250 and 500 mkd, respectively (Table 3). The Cyp4a10 transcript was increased to a lesser degree in the animals treated for 14 days (122.2-and 85.9-fold for 250 and 500 mkd, respectively) compared with 7 days (Table 3) . The lack of a dose-response at the highest dose level may be attributed to longer-term hepatic toxicity. Cyp1a1 was not appreciably induced with fold changes of 0.8-, 0.8-, 1.6-, and 3.7-fold at 5, 20, 250, and 500 mkd, respectively (Table 3) .
Consistent with the 7-and 14-day treatment groups, the 28-day treatment gene expression signature for higher-dose (250 and 500 mkd) pronamide administration indicated activation of the CAR, PXR, and PPAR-␣ NRs, whereas AhR signaling was not altered in a manner consistent with direct AhR activation. Lower-dose pronamide administration (5 and 20 mkd) was also consistent with a sub-threshold dose for biologically significant NR activation for CAR, PXR, and PPAR-␣. Notably, the 500-mkd dose group had an apparent lack of a dose-response after 14-and 28-day treatment when compared with the 250-mkd group, presumably due to the effects of longer-term, high dose administration of pronamide, with concomitant hepatic toxicity (as detailed in the Hepatic Hypertrophy and Non-receptor Mediated Increase in Cell Proliferation sections).
Data from the recovery groups of the study indicated essentially a complete recovery from the gene expression changes that were induced following 28 days of pronamide administration. For this experimental group, the animals were returned to control diet for the entire 35-day recovery period. Of particular note, the Cyp2b10 levels in the 250-and 500-mkd recovery groups returned to control levels of 1.9-and 0.7-fold, respectively; these values were comparatively 145.6-and 134.2-fold after 28 days of treatment and before removal of the test material (Table 3) . The increases in PPAR-␣-associated transcripts in higher-dose pronamide administration seen at 28 days also were decreased to control levels in the recovery group.
Taken together, these gene expression data provide significant insight into the potential MoA for pronamide, and also provide further evidence that the tumorigenic effects induced by pronamide have thresholds and are not likely to occur below a defined dose range. Furthermore, activation of these NRmediated pathways was reversible after removal of pronamide from the diet of the treated animals.
Peroxisome proliferation analysis by transmission electron microscopy.
Based on the results of the gene expression analysis of the liver, which included a robust peroxisomal proliferative phenotype (consistent with PPAR-␣ agonist) liver samples were analyzed for the ultrastructural presence of peroxisomes by electron microscopy (EM).
Ultrastructural examination was performed on the livers of mice (four mice/dose group) given 0, 5, 20, 250, or 500-mkd pronamide for 28 days, along with groups of four mice from both the recovery control and 250-mkd recovery groups. Due to the excessive hepatic toxicity observed at 500 mkd following 28 days of treatment, electron microscopic evaluation of the livers for peroxisomal proliferation was confined to the 250-mkd recovery group. Additionally, 250 mkd was chosen as an appropriate recovery group as this was the tumorigenic dose in the carcinogenicity study. Evaluation of electron micrographs revealed an overall increase in the number of peroxisomes, increase in lipid vacuoles, and increased amounts of smooth endoplasmic reticulum in the hepatocyte cytoplasm of animals given 250 or 500 mkd relative to controls (representative images are presented in Fig. 2 and summarized in Table 3 ), and was interpreted to be treatment related. In the 5-or 20-mkd animals, there were no appreciable increases in the number of peroxisomes, cytoplasmic lipid vacuoles, or proliferation of smooth endoplasmic reticulum, relative to the control group, indicating a threshold for peroxisome proliferation. This threshold was consistent with the profile for induction of PPAR-␣-related transcripts.
Ultrastructural examination of livers from the recovery group animals (250 mkd) revealed no distinguishable differences with the number of peroxisomes, cytoplasmic lipid vacuoles, and/or amounts of smooth endoplasmic reticulum, when compared with its concurrent controls (representative images are presented in Fig. 2 and summarized in Table 3 ). These findings are consistent with the lack of hepatocyte hypertrophy observed by H&E examination of the 250-mkd recovery group animals and the return of Cyp4a10 and other PPAR-␣-associated transcripts to control levels.
FIG. 3.
Western blot analysis of liver microsomes for Cyp2b10 protein content. Seven-day dietary administration of pronamide to mice-induced Cyp2b10 protein in the liver in the 250-and 500-mkd groups, but was not detected in the control, 5, or 20-mkd groups. Results are shown from four (of 10) representative mice for each treatment group. PB(+) control was used for the detection of Cyp2b10 protein, but is not appropriate for quantitative comparison to pronamide-treated samples; (−) control represents microsomes from an untreated animal.
Hepatic Cyp2b Western blot protein analysis. As a result of the gene expression analysis, which indicated a significant elevation in Cyp2b10 transcript, analysis of the specific Cyp2b10 protein was conducted. The analyses were performed for all samples in the 7-day treatment group and were undertaken by Western immunoblotting. A representative illustration of the results is presented in Figure 3 , where four representative animals (of 10) are presented from each treatment group. The PB-treated positive control samples are included for antibody specificity and molecular weight confirmation, however are not appropriate for quantitative comparison with the pronamide-treated samples.
After 7 days of pronamide treatment there was a clear, doseresponsive increase in Cyp2b10 protein in mice treated with 250-or 500-mkd pronamide. These data are consistent with the gene expression analysis of Cyp2b10, where a notable increase in transcript was identified, as well as an apparent threshold for biologically significant induction. There was no evident expression of Cyp2b10 protein in any of the animals fed control diet, 5, or 20-mkd pronamide. The immunoreactive band visualized in the 250-and 500-mkd samples is consistent with the PB-treated, positive control samples, indicating specificity for Cyp2b10 protein. For samples within a given treatment group (i.e., control, 5, 20, 250, or 500 mkd), the levels of Cyp2b10 protein were similar among all samples, indicating a similar magnitude of responsiveness between the animals within each treatment group. Increases in Cyp2b10 protein content (along with gene transcript) is considered a specific biomarker of the causal key event of CAR activation in NR-mediated rodent liver carcinogenesis (Cohen, 2010; Elcombe et al., 2014; Lake, 2009 ).
Hepatic metabolic enzyme activity. As a result of the gene expression and Western blot analysis of the pronamide-treated liver, which indicated a significant elevation of Cyp2b10, a functional analysis of the Cyp2b10 enzyme was undertaken, using 7-pentoxyresorufin-O-dealkylase (PROD) liver enzyme activity as the metric. Increased PROD enzyme activity is one of the primary alterations observed following a prototypical, PB-like, CAR activation (Lubet et al., 1985) . The analysis was performed for all samples in the 7-day treatment group. A summary of the results is presented in Table 3 , where the data are presented as foldchange versus control.
Surprisingly, there were no significant alterations in the PROD activity for any of the treatment groups compared with control after 7 days of pronamide treatment. There was, however, a clear 6.2-fold increase in Cyp2b-mediated PROD activity in PB-treated microsomes that served as positive control samples when compared with control (data not shown), indicating adequate specificity of the assay system to detect Cyp2b-mediated enzymatic activity. These results for the pronamidetreated samples were unexpected, given the clear increase in Cyp2b10 transcript and protein content in the 250-and 500-mkd-treated samples.
A number of studies using structurally diverse compounds have previously demonstrated inhibition of specific cytochrome p450 activity while increasing the expression of the relevant gene and the protein levels. Inhibition of cytochrome p450 activity may occur as a result of substrate competition, metabolic intermediate complexation, or mechanism-based (suicide) inhibition (Halpert, 1995; Murray and Reidy, 1990) . Hence, as detailed in the Discussion section, the lack of PROD activity in pronamidetreated livers does not indicate a lack of CAR-mediated activity; in fact, CAR activation is supported by increased gene transcript and protein expression of Cyp2b10. In vitro experiments were conducted to investigate the mechanism of the lack of PROD activity and are described below. Furthermore, the clear increase in total cytochrome p450 content (including relevant histopathological analysis and summarized in Table 3 ) indicates the induction of cytochrome content in the liver of pronamide-treated animals. The lack of PROD induction is not contradictory to the direct, causative nature of CAR NR activation in rodent hepatocarcinogenesis, given the understanding of the biochemistry of suicide inhibition and the strong supporting evidence for NR activation.
As previously described, the gene expression data from the livers of pronamide-treated mice also indicated a clear, robust induction of the PPAR-␣ NR. Specific biochemical characterization of peroxisome proliferation (e.g., acyl CoA oxidase enzymatic activity) was not undertaken as a result of the definitive demonstration of increased peroxisomal content by EM (Fig. 2) . The clear phenotypic induction of peroxisomes provides strong associative support as a specific biomarker for the activation of PPAR-␣ (Cohen, 2010) . Taken together, the associative measures of CAR/PXR and PPAR-␣ NRs support activation of these receptors in response to higher-dose pronamide treatment, and the data are consistent with an NR-mediated MoA for the hepatic effects.
In vitro assay for mechanism-based (suicide) inhibition of p450 enzyme activity. As previously indicated, pronamide induced robust increases in Cyp2b10 transcript and protein; however, there was no associated change in the activity of the enzyme as measured by PROD. To investigate the role for suicide inhibition in this paradoxical finding, in vitro experiments were conducted with PB-induced microsomes. These microsomes were coexposed to the pentoxyresorufin substrate in conjunction with either PB (negative control for inhibition), curcumin (positive control for inhibition; Thapliyal and Maru, 2001) , or pronamide and evaluated for PROD activity. PB had no effect on PROD activity, whereas curcumin had a dose-related inhibition of Cyp2b-mediated PROD activity of up to 63% at 40M (as shown from the representative experiment presented in Fig. 4 ). Similar to that of the positive control curcumin, pronamide inhibited PROD activity in a dose-related manner up to 61% at 500M. Consistent results were noted between replicate runs. These results indicate that pronamide and/or its metabolites irreversibly inhibit Cyp2b10-mediated PROD activity and elucidate the apparent inconsistency between protein levels and enzyme activity FIG. 4 . In vitro assessment of PROD enzymatic activity using PB-induced rodent liver microsomes. PROD (pentoxyresorufin-O-dealkylase) enzymatic activity was measured following addition of PB (negative control for suicide inhibition), curcumin (positive control for suicide inhibition), or pronamide. All test materials were administered in 0.1% DMSO, which served as the solvent control. Data presented are from a representative experiment (Run no. 3). Error bars represent standard deviation of technical replicates.
of pronamide-treated livers. These data also indicate that gene transcript analysis is more appropriate for an evaluation as a biomarker of NR pathway activation versus a functional analysis of the liver enzyme activity (e.g., PROD).
Hepatic cytochrome p450 protein content. As a result of the gene expression analysis that indicated a significant elevation in Cyp2b10 and Cyp4a10 transcripts, analyses of the total cytochrome p450 content were undertaken. The analyses were performed for all samples in the 7-day treatment group. Total p450 protein content was measured by spectrophotometric comparison of the reduced form (carbon monoxide exposed p450s) versus unreduced for each of the individual samples. There was a clear, dose-related increase in total p450 content relative to control from the pronamide-treated mouse liver microsomes ranging from 4.448 nmol p450/g tissue in the control group to levels of 20.357 nmol p450/g tissue in the 500-mkd group (data not shown). When expressed as fold-change relative to control, pronamide treatment resulted in a 3.4-and 4.6-fold increase after 250 and 500 mkd, respectively (summarized in Table 3).
Increased liver weights.
Although not direct evidence of causality of NR-mediated hepatic effects, liver weight data from the MoA study are representative of the treatment-related increases in liver weights that result from pronamide dietary administration. These changes are consistent with those commonly seen with administration of PB or peroxisome proliferators.
In general, there was a clear dose-and temporally-related increase in liver weights (both absolute and relative) in mice administered high doses of pronamide. After 7 days of pronamide administration, animals treated with 250-or 500-mkd pronamide had statistically identified treatment-related increases in mean absolute and relative liver weights when compared with control. In particular, the 250-mkd treatment group mean relative liver weights (i.e., liver weight to body weight ratio) were increased 81%, whereas at 500-mkd mean relative liver weight was increased 132% (Table 3) .
Similar liver weight changes were noted in animals administered pronamide for 14 days. In addition, a non-statistically identified increase of 6% was also noted in the mean relative liver weight of animals given 20 mkd of pronamide, when compared with control. Increases in liver weights were associated with microscopic hepatocyte hypertrophy only for mice exposed to 250-or 500-mkd pronamide for 7 or 14 days (as described below).
The mean liver weight changes were similar in animals administered pronamide for 28 days compared with the 7-or 14-day duration. In particular, animals treated with 250 mkd had a statistically identified increase of 88% for relative mean liver weight and animals given 500-mkd pronamide had a mean relative liver weight increase of 151% after the 28-day duration of pronamide administration. In addition, statistically identified, treatment-related increases were also noted in animals given 20 mkd of pronamide, wherein the mean relative liver weights were increased by 10% when compared with control. Increases in liver weights were associated with microscopic hepatocyte hypertrophy only for mice exposed to 250-or 500-mkd pronamide for 28 days (as described below).
The liver weight changes induced by pronamide administration robustly regressed after cessation of exposure to the test material. There was, however, a statistically identified mean relative liver weight change in animals given 500 mkd of pronamide for 28 days of treatment and following a subsequent 35-day recovery period. Specifically, the previously described mean relative liver weight increases attributed to 28 days of pronamide administration of 151% reverted to an increase of 17% over controls subsequent to the 35-day recovery period.
Additionally, liver weight data from other mouse studies were considered in this analysis, including a standard dietary 28-day study (unpublished study report: Stebbins et al., 2002) and a carcinogenicity study (unpublished study report: (Stebbins and Brooks, 2004) ). Although the administered doses differed slightly, liver weight changes were similar to those seen in the MoA study (data not shown, although qualitatively summarized in Table 5 ). In the 28-day study, statistically identified and treatment-related increases in relative liver weight were identified at 75, 375, and 1000 mkd, whereas no remarkable alterations were noted in animals administered 15 mkd. After 18 months of administration, mice administered 50-or 250-mkd pronamide had statistically increased absolute and relative liver weights, whereas 5 mkd did not induce a treatment-related increase in liver weight. The magnitude of liver weight alterations was predictive of the hepatocarcinogenic effect of pronamide administration where 5 and 50 mkd (non-carcinogenic doses) induced increases in relative liver weight of 4 and 25% above control, respectively; whereas 250 mkd (carcinogenic dose) induced a relative liver weight of 286% of control. At the end of the 18-month study these differences in liver weights also reflected, in part, a significant increase in incidence of hepatocellular adenomas and carcinomas (Table 1) .
In total, evaluation of liver weights from mice over a range of study durations (7 days to 18 months), and a range of dietary dose levels of pronamide (5 to 1000 mkd), is supportive in regard to correlation with hepatic NR activation, the first key event for liver tumor induction. As previously described, liver weight changes offer indirect, supporting evidence related to the key event 1 in NR-mediated rodent liver tumorigenesis.
Hepatocellular hypertrophy. The increased liver weights associated with pronamide administration in the mouse corresponded with the histologic observation of hepatocellular hypertrophy. For this analysis, the data for the centrilobular and panlobular hepatocellular hypertrophy and level of severity were consolidated for presentation and are summarized in Table 3 .
Although not direct evidence of causality for NR-mediated hepatic effects (in this case CAR/PXR and PPAR-␣), the previously described liver weight increases and microscopic hepatocellular hypertrophy provide associative support for the NR activation key event of this MoA (Cohen, 2010; Elcombe et al., 2014) . These hepatic alterations are commonly seen following exposure to NR-activating compounds, such as PB or peroxisome proliferators. Similar to the liver weight changes, microscopic hepatocellular hypertrophy also exhibited a threshold, dose-responsive alteration, both in severity and in the incidence of the histopathology. Furthermore, these alterations were consistent with the dietary concentrations that resulted in hepatocellular tumors in the mouse carcinogenicity studies. Again, as with liver weight increases, clear specificity for the pronamide hepatic alterations was demonstrated by reversibility of the microscopic hepatocellular hypertrophy after removal of the test compound and administration of control diet, i.e., after 28 days of treatment of up to 500-mkd pronamide eight of 10 animals had hypertrophy graded slight and the other two animals were graded very slight, whereas following 35 days of recovery no animals were graded with any level of severity of hypertrophy and were considered to have reverted to a normal histological appearance (incidence data summarized in Table 3 ).
The treatment-related histopathologic effects related to NRactivation that were observed in the livers of mice consisted of a dose-related increase in the severity of hepatocellular hypertrophy, with altered tinctorial properties (increased eosinophilia) involving the centrilobular to midzonal regions of the hepatic lobule. In addition, higher dose administration of pronamide resulted in increased vacuolization in centrilobular-to-midzonal hepatocytes, although Oil Red O staining was not undertaken to evaluate lipid content. These changes are consistent with those from a cytochrome p450 inducer and CAR activator (Peffer et al., 2007) . Evaluation of the data for microscopic hepatocellular hypertrophy in mice over a range of study durations (7 days to 18 months) and dietary dose levels of pronamide (5 to 1000 mkd) are informative in regard to correlation with liver weights and NR activation (although only the specific MoA study data are summarized in Table 3 ).
FIG. 5. Hepatocellular proliferation in mice administered dietary pronamide.
BrdU-labeled hepatocyte labeling indices were determined by immunohistochemical staining and were quantitated in each of the three hepatolobular zones (1000 total hepatocytes/animal/zone). The data were summed and are presented as a panlobular total for the treatment group (n = 10 animals) expressed as means and error bars represent standard deviation. * Statistically identified, Dunnett's test, ␣ = 0.05.
Hepatocellular proliferation.
Immunohistochemical staining for BrdU-labeled nuclei as a measure of hepatocellular proliferation was based on interpretation of the nuclear staining intensity and an approximation of the location within the three hepatolobular zones. The data are presented as fold-change in the text and represent the difference between the respective treated group and control based on a minimum of 1000 hepatocytes evaluated in each of the three hepatic zones for each animal but are combined and presented as panlobular for presentation purposes (Fig. 5) .
Hepatocellular proliferation analysis after 7 days of 250-or 500-mkd pronamide administration in mice resulted in a statistically significant increase in stained cells, when compared with those of the control group in the centrilobular (14.5-or 21.8-fold, respectively), midzonal (20.1-or 29.8-fold, respectively), and periportal (20.1-or 32.8-fold, respectively) regions (data not shown). The totaled panlobular counts were also statistically identified at the 250-or 500-mkd dose level after 7 days of pronamide administration and are presented in Figure 5 . Importantly, there was no biologically or statistically identified increase in hepatocellular proliferation in any zone when treated with the non-carcinogenic doses of 5-or 20-mkd pronamide, indicating a clear threshold for pronamide-induced hepatocellular proliferation after 7 days of treatment.
The trend of hepatocellular proliferation was similar, but less robust, in animals treated with 14 days of pronamide by dietary administration when compared with 7 days. For this treatment group, BrdU was administered via an osmotic pump for the last 7 days of treatment. Specifically in animals treated with 250 mkd there was a statistically identified increase in the proliferation index in centrilobular, midzonal, and periportal counts of 5.8-, 5.1-, and 7.2-fold, respectively, when compared with control animals (data not shown). Animals treated with 500-mkd pronamide had statistically identified and dose-responsive increases in hepatocellular proliferation in centrilobular, midzonal, and periportal counts of 10.7-, 7.7-, and 10.3-fold, respectively. Consistent with the hepatocellular proliferation data after 7 days, the animals treated with 5-or 20-mkd pronamide for 14 days were indistinguishable from the control levels of proliferation, and total (panlobular) data are presented in Figure 5 . These comparatively decreased quantitative fold-increases in high dose pronamide-treated mice (compared with 7 days of treatment) are consistent with an initial proliferative burst within the first week of treatment, associated with NR-mediated hepatocellular proliferation (reviewed in Lake, 2009).
Twenty-eight days of pronamide administration was analogous in many respects to the proliferative effects of shorter duration treatment, where 5 and 20 mkd were comparable with control levels. Statistically identified increases in hepatocellular proliferation for 250-mkd pronamide in centrilobular, midzonal, and periportal counts were quantified as 4.2-, 5.3-, and 5.1-fold, respectively (data not shown). Interestingly, administration of 500-mkd pronamide for 28 days increased hepatocellular proliferation to fold increases similar to the 7-day treatment duration with centrilobular, midzonal, and periportal counts of 29.5-, 24.8-, and 17.7-fold, respectively (individual zone data not shown, but panlobular data presented in Fig. 5) .
The induction of hepatocellular proliferation was completely reversed in animals treated for 28 days and allowed to recover for a total of 35 additional days (with a BrdU osmotic pump present for the last 7 days of recovery). There were no statistically significant increases in hepatocellular proliferation at any dose level or in any of the hepatolobular regions analyzed. Notably, there was a statistically identified "decrease" in proliferation in all regions that had been statistically increased after 28 days of treatment. Specifically, decreases in centrilobular, midzonal, and periportal counts of −3.9, −4.2-, and −4.4-fold, respectively, were present in animals initially treated with 250-mkd pronamide before recovery (data not shown). Similarly, in animals treated with 500-mkd pronamide "decreases" in centrilobular, midzonal, and periportal counts of −4.1-, −3.3-, and −3.9-fold, respectively, were identified (individual zone data not shown, but panlobular data presented in Fig. 5 ). These data support a direct, causative effect of pronamide on hepatocellular proliferation, as cessation of exposure to test material for 35 days resulted in a decrease in proliferation compared with controls.
In addition, in the standard 28-day study in mice, there was a treatment-related increase in the overall numbers of hepatocytes in mitosis in the animals treated with 375-or 1000-mkd pronamide when compared with control animals (unpublished study report: Stebbins et al., 2002; data not shown) . This is consistent with the general dose-related increase in hepatocellular proliferation noted in the molecular (BrdU) MoA proliferation analyses.
In conclusion, there was a clear dose-, hepatolobular zoneand duration-related induction of hepatocellular proliferation in mice treated with pronamide by dietary administration. The induction of hepatocellular proliferation also exhibited a clear threshold, where at subcarcinogenic dose levels, no increase in proliferation was identified. Furthermore, this treatmentrelated proliferative induction regressed following test material withdrawal and indicated compensatory decreases in proliferation when compared with control groups. In total, the data generated with respect to treatment-related hepatocellular proliferation provide strong correlative evidence on the role for activation of NRs (i.e., CAR/PXR and PPAR-␣) as a key event in the MoA of the response.
Hepatocellular foci.
Increased hepatocellular proliferation is a key event for an NR-mediated MoA for hepatocellular carcinogens. Long-term, sustained increased hepatocellular proliferation leads to the induction of proliferative lesions within the liver, including foci, adenomas, and eventually carcinomas (Co-hen, 2010; Elcombe et al., 2014) . The incidence of liver foci in male CD-1 mice from the carcinogenicity study is listed in Table 4 (unpublished study report: Stebbins and Brooks, 2004) .
Although development of altered hepatic foci is sometimes listed as a key event for NR-mediated MoAs, the foci are a reflection of the hepatocellular proliferation (Thoolen et al., 2010) , which is the actual key event that leads to selective clonal expansion resulting in the formation of microscopic hepatocellular foci and the subsequent development of adenomas and/or carcinomas. With respect to pronamide, the mouse carcinogenicity study identified clear increases in basophilic, eosinophilic, and clear/vacuolated foci in the high dose (250 mkd) mice, but were not found at non-hepatotumorigenic dietary concentrations of 5 or 50 mkd (Table 4 ). The recent publication by Cohen (2010) does not include hepatocellular foci as a specific key event in the data necessary to support an NR-mediated MoA.
DISCUSSION
A critical factor in establishing an MoA is an evaluation of the evidence using the Bradford Hill criteria, indicating the strength, consistency, and specificity of the data supporting the key events, along with biological plausibility and coherence. Activation of specific NRs in rodents constitutes a recognized MoA for rodent hepatocarcinogens (Cohen, 2010) with the early key events for this MoA as: (1) NR activation, with associated cytochrome isozyme induction and peroxisome proliferation, and (2) an increase in hepatocellular proliferation that results in subsequent foci, adenomas, and eventually carcinomas. In addition to these key events in the pathogenesis of hepatocellular tumors in rodents, demonstration of reversibility of early hepatic effects upon discontinuance of treatment is considered important data to address specificity and support this MoA (Cohen, 2010) . In the case of pronamide, mechanistic and apical data clearly indicate the activation of both the CAR/PXR and PPAR-␣ signaling pathways (key event 1) that then converge on the common key event of increased hepatocellular proliferation (key event 2).
When taken together, the MoA and repeat-dose toxicity studies for mice described above clearly demonstrate a pronamideinduced, robust, dose-related increase in NR-mediated signaling. This includes the CAR-associated Cyp2b10 transcript and associated increase in specific Cyp2b10 protein, as well as PPAR-␣-associated Cyp4a10 and other peroxisome-related transcripts. These results are consistent with the direct activation of the CAR/PXR and PPAR-␣ NRs. Although CAR-associated PROD enzyme activity was not shown to be induced, an in vitro analysis demonstrated suicide inhibition of the relevant enzymatic activity in a dose-related manner with pronamide. An overview schematic of the molecular and apical data that support the activation of the CAR/PXR and PPAR-␣ NRs in the liver of pronamidetreated mice is presented in Figure 6 . In addition, analysis of hepatocellular proliferation indicates a clear, thresholded, doserelated induction of proliferation at the carcinogenic dose of pronamide but not at lower dose levels. Furthermore, the molecular and apical effects of pronamide on the liver were reversible upon recovery following withdrawal of the test material, including hepatocellular proliferation. Lastly, the NR-associated gene expression and protein data from these MoA experiments in mice define a very specific MoA while, simultaneously, ruling out other NR-mediated MoAs for rodent hepatic carcinogens such as AhR agonism.
As previously summarized, other pronamide repeat-dose dietary studies in mice, over a range of study durations and dose levels, also demonstrate a consistent dose-related association with the key events based on liver weights, microscopic hepatocellular hypertrophy, and hepatocellular proliferation data. Although alterations were identified in centrilobular/panlobular hypertrophy (slight) and relative liver weight increases (20%) at 75 mkd after 28 days, as well as Cyp2b10 and Cyp4a10 transcript increases at 20 mkd (3-6% of the magnitude of the carcinogenic dose of pronamide), these minor changes are not consistent with a causal key event phenotype. Ultimately, taking into consideration the mouse cancer study, as well as the shorter-term studies, non-tumorigenic doses of pronamide were not associated with substantial alterations in the key events and/or associated effects, whereas higher dose levels (250 mkd and above) resulted in NR activation, hypertrophy, proliferation, and hepatocellular tumors (summarized in Table 5 ).
Biological Plausibility and Coherence
Dietary administration of pronamide to mice results in the early key events (NR activation and hepatocellular proliferation) that can lead to hepatocellular tumors in mice after prolonged exposure to high dose levels of pronamide (250 mkd and above). The early biological responses associated with the key event of NR activation (i.e., gene expression biomarkers, hepatocellular hypertrophy, peroxisome proliferation, and hepatocellular proliferation) are reversible upon cessation of treatment with pronamide. The MoA demonstrated for pronamide is consistent with the established MoA for NR activation (i.e., CAR/PXR and PPAR-␣) in rodents (Cohen, 2010; Corton et al., 2014; Elcombe et al., 2014) and the MoA is consistent with a current understanding of cancer biology and non-genotoxic, NR-mediated carcinogenesis. Ideally, a further determination of the role of the NRs could have been undertaken using genetically engineered murine models (i.e., CAR/PXR/PPAR-␣ triple knockout mice); however, to the best of our knowledge, these animals are not commercially available. Future investigations could include characterization of the mechanistic and apical responses of these knockout animals using the carcinogenic dose of pronamide.
With respect to suicide inhibition of the Cyp2b10-mediated PROD enzymatic activity, activation of CAR is the actual key event and was clearly demonstrated. Cyp2b10 gene transcript, protein, and functional activity all serve as biomarkers for receptor activation; these biomarkers are not key events in the pathway, per se, but are reliable indicators of CAR activation. Thus, the lack of induction of functional PROD activity, demonstrated to be due to the suicide inhibition of Cyp2b10 activity by pronamide, is not evidence against CAR activation, although the exact mechanism for CAR activation has not been elucidated. For example, in the rat and dog, the antibiotic chloramphenicol has been shown to be a mechanism-based inactivator of PB-induced (i.e., Cyp2b family) cytochrome p450 activity (Ciaccio et al., 1987; Halpert, 1995) . Furthermore, a number of studies have extensively investigated a similar case for the mechanism of musk xylene-induced inhibition of PROD activity. Similar to pronamide, musk xylene has been shown to induce Cyp2b10 transcript and protein without a concomitant increase in PROD activity (Lehman-McKeeman et al., 1995 , 1997 . Also similar to pronamide, musk xylene is non-genotoxic and causes increased hepatocellular tumors in mice, presumably mediated through CAR activation. Lastly, the chemical structure of pronamide (Fig. 1) contains an acetylene moiety, which has been shown in a number of publications to be an important functional group in a wide array of suicide inhibitors, including the Cyp2b family of cytochrome p450s (reviewed in Hollenberg et al., 2008) . Hence, the lack of PROD activity in pronamide-treated liv- ers does not indicate a lack of CAR-mediated activity; in fact, CAR activation is supported by gene expression and protein expression of Cyp2b10, and given the in vitro metabolism results demonstrating suicide inhibition of PROD activity by pronamide, no induction of PROD would be expected.
As previously mentioned, most of the work that has been performed in the characterization of NR pathways and downstream effects has been with prototypical CAR/PXR and PPAR-␣ agonists, and historically these data have been shown as activating for one pathway and inhibitory or non-effectual for the other one (Guo et al., 2007) . A number of recent publications on different classes of compounds, however, have begun to elucidate a multiple NR activation MoA that activates both CAR and PPAR-␣. Perfluorocarboxylic acids (perfluorooctanoic acid and perfluorodecanoic acid) and DEHP (Di-(2-ethylhexyl)-phthalate) were thought to be unilateral PPAR-␣ agonists. Recent studies, however, have indicated that CAR-mediated activation occurs (i.e., PB-like activity) along with PPAR-␣ activity (Cheng and Klaassen, 2008; Eveillard et al., 2009; Ren et al., 2010; Rosen et al., 2008b,a; Wolf et al., 2008) . In these studies, wild-type, CAR-null, and PPAR-␣-null mice were used to investigate NR involvement in response to chemical administration. In summary, the results from these gene expression studies indicate that the aforementioned compounds produced an NR-mediated MoA with clear involvement of both CAR and PPAR-␣ NRs by the same parent compound (reviewed in Elcombe et al., 2012; Klaunig et al., 2012) . Interestingly, the results from the perfluorocarboxylic acids and DEHP studies indicated generally reduced activity for one pathway in the presence of the other, i.e., when one receptor is knocked out, the agonistic activity of the ligand for the remaining pathway was increased. Lastly, data from a recent publication on a series of triazole fungicides demonstrated coactivation of the CAR and PPAR-␣ NR in the liver of mice treated with tebuconazole (Tamura et al., 2013) . In that study although the magnitude of Cyp2b10 gene expression increase was similar to that of pronamide, Cyp4a10 was not induced to similar levels (Ͻ10-fold), the liver weight change was substantially less, and investigation of peroxisome proliferation/content was not undertaken. Interestingly, for pronamide each NR pathway was seemingly maximally activated when compared with known activators of each receptor individually, based on their respective cytochrome p450 gene expression levels Stagg et al., 2012) . These data for pronamide are consistent with the known MoA for PB and other CAR/PXR activators, as well as the MoA established for PPAR-␣-related peroxisome proliferators. The large body of current evidence indicates that humans are refractory to the hepatotumorigenic effects of both CAR/PXR activation and peroxisome proliferators and that the NR-mediated MoA for CAR/PXR and PPAR-␣ are highly similar (reviewed in Cohen, 2010; Corton et al., 2014; Elcombe et al., 2014; Holsapple et al., 2006; Klaunig et al., 2003; Lake, 2009 , and references therein).
Inhibition of apoptosis may be listed as a separate key event for an NR-mediated MoA; however, hepatocellular apoptosis may not be observed as a component of a PB-like effect in a mouse because mouse hepatocytes do not enter apoptosis as readily as rat hepatocytes (Bursch et al., 2005; Lake, 2009) . Also inhibition of apoptosis as a component of a CAR/PXR-like hepatocellular tumor MoA primarily pertains to the tumorigenic progression of preneoplastic hepatocytes within foci of altered cells rather than other normal hepatocytes (Kolaja et al., 1996; Lake, 2009; Schulte-Hermann et al., 1989 , 1990 Whysner et al., 1996) . In addition, standard regulatory studies do not typically provide quantitative data on the incidence of apoptosis in the liver or other tissues, and short-term mechanistic studies are not long enough to induce the foci necessary for apoptosis evaluation. With respect to pronamide, no molecular characterization of apoptosis was undertaken. The recent publication by Cohen (2010) does not include inhibition of apoptosis as a data requirement necessary to support a CAR/Cyp or a PPAR-␣ MoA for hepatocarcinogenesis. The recent publication by Elcombe et al. (2014) identifies the role of the inhibition of apoptosis as an associated event in CAR-mediated toxicity, but not as a key event. Regarding the PPAR-␣ MoA, Corton et al. (2014) described experimental evidence that demonstrated both a suppression of apoptosis during the initial, short-term burst of increased cell proliferation and a possible slight increase in apoptosis after chronic administration of some PPAR-␣ activators. The authors indicated that PPAR-␣ may balance the levels of cell proliferation and apoptosis to maintain a new steady state within the liver. Overall, Corton et al. concluded that alteration of hepatocyte function via induction of cell proliferation and/or inhibition of apoptosis was a key event in the PPAR-␣ MoA. Both reviews highlighted that much of the work on the role of apoptosis was from in vitro studies in hepatocytes, as it is technically difficult to demonstrate a suppression of apoptosis relative to a low endogenous signal in young rodent livers.
The data for pronamide are judged to adequately explain the development of hepatocellular tumors in mice following high-dose chronic dietary administration of pronamide with a high degree of confidence. The analysis of the CAR/PXR-and PPAR-␣ NR-mediated MoA clearly demonstrated consistency and strength of association, with expected dose-related, tempo-ral, and specificity attributes, along with biological plausibility and coherence, as summarized in Table 6 .
Examination of Alternative Possible MoAs for Pronamide-Induced Rodent Liver Tumors
The recognized MoAs for rodent hepatocellular carcinogenesis are broadly categorized as (1) increased cell proliferation (i.e., mitogenic, which can be subcategorized as either receptor-or non-receptor-mediated) or (2) DNA reactivity (Cohen, 2010) .
Receptor-Mediated, Increased Cell Proliferation
MoAs for hepatocellular carcinogens that cause receptormediated hepatocellular proliferation include CAR, PXR, PPAR-␣, and AhR activation, as well as estrogens and statins (Cohen, 2010) . The liver MoA studies in mice with pronamide clearly demonstrate a specific, dose-related increase in the CAR/PXR and PPAR-␣ NR activation via Cyp2b10/Cyp3a11-and Cyp4a10-associated transcripts, respectively, with associated increases in Cyp2b10 protein and peroxisomes. Taken together, these findings are consistent with direct activation of the CAR/PXR and PPAR-␣ NRs. At the same time, the MoA studies in mice ruled out AhR-mediated MoA as the Cyp1a1 transcript was not altered in a manner consistent with a direct activator of AhR (Boverhof et al., 2006) and small non-specific increases in Cyp1a1 have been identified with other CAR activators (Corcos et al., 1998; Geter et al., 2014; Hu et al., 2007) .
Estrogens have a specific receptor-mediated MoA that results in cell proliferation in tissues including the liver; however, the carcinogenic activity may be due to an interaction of DNA adduct formation with increased cell proliferation (dual MoA) (Cohen, 2010) . Pronamide is not likely to have an estrogenic MoA based on structural dissimilarity to estrogens, and, in addition, there is no evidence of estrogenic activity from a two-generation toxicity study in the rat (unpublished study report: Solomon and Brown, 1990 ; data not shown) or any of the recently conducted USEPA Endocrine Disruptor Screening Program assays. These include, in vitro ER binding activity, in vitro ER transcriptional activity, uterotrophic, and female pubertal assays (unpublished study reports: LeBaron and Kan, 2012; Marty et al., 2011 Marty et al., , 2012 data not shown) .
Statins are a class of chemicals that act through inhibition of a specific enzyme, HMG-CoA-reductase, which leads to marked reduction in cholesterol production in humans (Cohen, 2010) , but not in rodents (Endo et al., 1979) . Epidemiologic evidence in human patients demonstrates that statins are not associated with an increase in liver or other tumors (Farwell et al., 2008) . Thus, a statin MoA for liver tumors in rodents appears to be irrelevant to human carcinogenesis based on understanding the mechanism and extensive epidemiologic evidence (Cohen, 2010) . Statins increase hepatocellular proliferation and hepatocellular tumors in rodents (MacDonald and Halleck, 2004) ; however, statins do not decrease serum cholesterol in rodents. Serum clinical chemistry values in mice indicated that treatment with pronamide largely did not affect serum cholesterol levels; however, there was an increase (35%) in the animals treated with 500 mkd for 28 days, which correlated with histopathological and serum markers of remarkable hepatic cytotoxicity (data not shown). Overall, in subchronic studies, the lack of concordant localized periportal atypia and bile duct hyperplasia indicates that the hepatic effects seen with pronamide administration are not consistent with known statin effects in the rodent liver (MacDonald et al., 1988) .
Non-receptor-Mediated, Increased Cell Proliferation
MoAs for hepatocellular carcinogens that cause non-receptormediated, increased cell proliferation include cytotoxicity, infection, iron (copper) overload, and increased apoptosis, e.g., fumonisin B1 (Cohen, 2010) . Cytotoxicity is unlikely to be a relevant and major contributing factor in the MoA for pronamideinduced hepatocellular tumors in mice. There was evidence of slight histological hepatotoxicity at the carcinogenic dose level (250 mkd) that included very slight to slight necrosis of hepatocytes with accompanying inflammation and necrosisrelated serum endpoints (i.e., ALT, AST, and alkaline phosphatase) in the 28-day MoA study (serum clinical chemistry and liver histopathology data are summarized in the Supplementary data section (Supplementary Appendix tables 2-9) . The data suggest, however, that these alterations are a non-specific result of the pronamide-induced CAR/PXR and PPAR-␣ activation, subsequent cytochrome p450 induction, and robust histological hepatocellular hypertrophy and, hence, are not a primary cytotoxic effect of pronamide. Similar levels of mild liver necrosis, evidence of cytotoxicity, and/or accompanying clinical chemistry changes at higher dose levels have been observed for other CAR and PPAR-␣ activators in mice as well (Peffer et al., 2007; Peters et al., 1998; Ward et al., 1988) , and it has been suggested that a higher level of oxidative stress in the presence of peroxisome proliferation or sustained Cyp induction may be a contributing factor (Corton et al., 2014) . Furthermore, these NR activators also produce a time course of hepatocellular proliferation that extends beyond the 1-7-day burst that is typical for PB, which is also similar to the pattern observed for pronamide after 14 or 28 days of treatment at the carcinogenic dose of 250 mkd. The severity of these cytotoxic alterations with pronamide at 250 mkd was not consistent with the robust induction of proliferation at early timepoints, and this lack of temporal and severity concordance indicates that a direct mitogenic (NR-mediated) effect on the hepatocytes of animals treated with high doses of pronamide is the operative MoA.
This conclusion is supported by the extension of the doseresponse curve for hepatic cytotoxicity at higher dose levels of pronamide (500-1000 mkd) in other short-term studies where moderate to severe necrosis was noted, along with body weight and feed consumption decrements (data not shown). If cytotoxicity-induced regenerative proliferation were an operant MoA, one would expect to see increased proliferation over time that correlated with the magnitude of cytotoxicity, e.g., as seen with carbon tetrachloride, as well as other long-term liver changes associated with chronic cytotoxicity such as fibrosis. Taken together, the weight of evidence does not support a consistent association of cytotoxicity/necrosis in pronamidetreated animals as a causal driver of hepatocellular tumors.
An infectious MoA is not relevant for pronamide as minimal indications of hepatocellular toxicity or chronic active inflammation of the liver were noted, in comparison with that which is seen by an infectious agent. Pronamide does not appear to result in hepatic accumulation of iron or copper based on histopathological findings in the liver for studies of multiple durations in mice (although no specific staining was undertaken), nor are there indications of extensive areas of necrosis with regenerative response, hence this is not a potential contributing MoA for the mouse liver tumors. Lastly, pronamide did not increase apoptosis in any of the previously described toxicity studies, although no direct measure was undertaken beyond standard histopathological analysis. In addition, as was previously described, the NR-mediated MoA typically decreases apoptosis in initiated, proliferative foci of altered cells. Thus, the Brusick, 1975; Fabrizio, 1973; Kumaroo and Melhorn, 1987; Shirasu et al., 1978; Sibinovic, 1973; Tippins et al., 1984; Wagner and Hines, 2008) ; data not shown, although summarized in Supplementary data; Supplementary
Appendix table 1). Additionally, an in vivo mouse micronucleus assay showed that pronamide does not induce micronuclei in somatic cells or an increase in unscheduled DNA synthesis in primary rat hepatocytes (unpublished study reports: Muller and Frank, 1987; Sames et al., 1984) . An evaluation of the genetic toxicity data for pronamide unequivocally supports a lack of DNA reactivity and hence this is not a potential MoA for the induction of hepatocellular tumors in mice. A summary evaluation for other possible MoAs for the pronamide-induced rodent liver tumors is presented in Table  6 . Evaluation of the data for pronamide against the alternative MoAs clearly indicates that these alternative MoAs are not likely to be relevant.
PRONAMIDE MOUSE LIVER TUMOR HUMAN RELVANCE FRAMEWORK
Question 1. Is the Weight of Evidence Sufficient to Establish the MoA in Animals?
The answer is yes. The MoA for pronamide-induced mouse liver tumors is compatible with that described for NR-mediated rodent liver tumors (Cohen, 2010; Corton et al., 2014; Elcombe et al., 2014; Holsapple et al., 2006; Klaunig et al., 2003; Lake, 2009; Whysner et al., 1996) . The relevant molecular and pathological endpoints for pronamide-induced liver effects in mice are supported by pronamide repeat-dose mouse studies, and there is good correlation for the dose-response between the MoA data and the hepatocellular tumors. Key event 1 for the pronamide mouse liver tumor MoA was demonstrated by induction of the Cyp2b10 transcript and protein and Cyp4a10 and other peroxisome-associated liver transcripts and electron microscopic identification of increased hepatic peroxisomes and cytoplasmic smooth endoplasmic reticulum. Although Cyp2b-associated liver enzyme activity (PROD) was not induced, in vitro mechanistic examination revealed that pronamide acts as a suicide inhibitor of PROD activity. Key event 2 is an increase in hepatocellular proliferation demonstrated only at the tumorigenic dose level and above, with no increase identified at non-carcinogenic doses. When all the mechanistic and standard studies for pronamide are analyzed, the key events show clear, thresholded, dose-responsive alterations and are consistent with an NR-mediated MoA (i.e., CAR/PXR and PPAR-␣ activation). Importantly, all the initial mechanistic and apical key events also demonstrated clear reversibility after removal of the test material, providing confirmation of specificity for these effects. The summary of the MoA data in a dose-temporality format is presented in Table 5 . In addition, alternative MoAs were examined and evaluated to be not plausible or at least unlikely based on analysis of the available data for pronamide.
Question 2. Can Human Relevance of the MoA Be Reasonably Excluded Based on Fundamental Qualitative Differences in Key Events between Experimental Animals and Humans?
The answer is yes. Activation of the CAR/PXR and PPAR-␣ NRs and subsequent induction of cytochrome p450 (Cyp) enzyme activity and of peroxisomes in the liver is a well-known MoA for rodent hepatocarcinogenesis (Cohen, 2010; Corton et al., 2014; Elcombe et al., 2014; Klaunig et al., 2003; Whysner et al., 1996) . Activation of rodent CAR/PXR and PPAR-␣ produces a cascade of alterations in gene transcription that leads to increased hepatocellular proliferation, a critical event in the development of liver tumors (Cohen, 2010; Corton et al., 2014; Elcombe et al., 2014; Klaunig et al., 2003; Whysner et al., 1996) . On the other hand, PB in humans results in activation of CAR and PXR leading to the induction of Cyp enzymes, although a different pattern of response is induced in humans compared with rodents (Lambert et al., 2009) and, more importantly, there is no evidence of increased hepatocellular proliferation in humans or primary human hepatocytes in vitro (reviewed in Elcombe et al., 2014; Lake, 2009) . Similarly for peroxisome proliferators, activation of PPAR-␣ does not lead to increased hepatocellular proliferation in humans or primary human hepatocytes (reviewed in Lake, 2009). Extensive epidemiologic studies in humans exposed to levels of PB comparable with those in rodent bioassays did not find an increased risk of liver cancer in humans (Elcombe et al., 2014; Lamminpaa et al., 2002; Whysner et al., 1996) , nor is there evidence of liver cancer in humans after pharmaceutical administration of fibrates and other PPAR-␣ activating compounds (reviewed in Klaunig et al., 2003) . Furthermore, genetically modified mice that have had the respective rodent receptors (CAR/PXR or PPAR-␣) replaced with human orthologs have demonstrated a lack of a proliferative effect after administration of the appropriate positive control compound (reviewed in Lake, 2009). Recent work has demonstrated, however, a transcriptional signature indicative of proliferation in humanized mice (for CAR and PXR) when given a sufficient dose of PB such that presence of the human receptor in murine hepatocytes may not completely recapitulate the human response Luisier et al., 2014) . Based on the MoA assessment, PB or peroxisome proliferators are not hepatocarcinogens in humans, presumably as a result of the divergent biological response with respect to hepatocellular proliferation. Therefore, a hepatocarcinogenic response in rodents for compounds that have data to support a CAR/PXR-mediated MoA is not relevant to humans (Cohen, 2010; Elcombe et al., 2014; Holsapple et al., 2006; Lake, 2009) .
A concordance analysis of the key events in rodents and humans for the NR-mediated MoA (CAR/PXR and PPAR-␣ activation) is presented in Table 7 .
Question 3. Can Human Relevance of the MoA Be Reasonably Excluded Based on Quantitative Differences in Either Kinetic Or Dynamic Factors between Experimental Animals and Humans?
Human relevance of the experimental animal CAR/PXRmediated MoA for liver tumors can be reasonably excluded on the basis of qualitative differences in key events (Question 2); a quantitative assessment of kinetic or dynamic factors relevant to a PPAR-␣-mediated MoA for liver tumors indicates that a substantial difference in species exists, such that rodent liver tumors are unlikely to be relevant to humans (reviewed in Corton et al., 2014, and references therein) . Although the molecular mechanism has yet to be completely described, studies with prototypical PPAR-␣ activators have identified quantitative differences in rodent versus human hepatic responses, consistent with a greater hepatic sensitivity in rodents. For example, (1) full length PPAR-␣ levels are 10-fold higher in the rodent than human (Choudhury et al., 2000) ; (2) humans have a truncated form of the PPAR-␣ receptor that acts a dominant-negative (Gervois et al., 1999) ; (3) even when expressed at levels similar to mouse PPAR-␣, human PPAR-␣ does not induce cell proliferation or liver cancer in mice (Morimura et al., 2006) ; (4) levels of PPAR-␣ response elements in target genes (e.g., AcylCoA Oxidase) differ between mice and humans . Hence, as detailed in Corton et al. (2014) , although no conclusive evidence has been identified for specifically determining whether a quantitative or qualitative difference in the MoA exists, the data support the MoA as unlikely to be relevant to humans. It has been demonstrated that there are significant toxicodynamic differences between rats/mice and human and importantly with respect to hepatocellular proliferation. On these bases, the mouse liver tumors associated with administration of high dose levels of pronamide would not pose a cancer hazard to humans.
CONCLUSION
The investigation of the MoA for pronamide-induced mouse liver tumors demonstrated dose-, temporal-, apical-, and molecular-concordance with an NR-mediated (i.e., CAR/PXR and PPAR-␣) effect, thus establishing the NR-mediated MoA for pronamide-induced mouse liver tumors. In addition, the data were consistent with a threshold for a carcinogenic response in the mouse liver when the MoA was evaluated below, at, and above the carcinogenic dose. Based upon previous MoA/HRF analyses and the current understanding of the biology of the carcinogenic response associated with NR activation in rodents, it is unlikely that pronamide would induce hepatocellular proliferation in humans and hence would not be a human liver carcinogen. Furthermore, these data indicate that measurement of transcript levels as biomarkers for NR activation is more appropriate than traditional enzyme activity measurements, especially in cases of suicide inhibition.
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